Calling all volunteers for Alzheimer’s, dementia research

Clinical trials test drugs and other interventions to see if they are safe and effective in people. Registries help match volunteers with studies that might be right for them. Both are valuable ways to participate in research on Alzheimer's and related dementias.   Click on the study opportunities below for details, including contact information.   Drugs A4: Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (multiple sites) Connect: AZD0530 in Mild Alzheimer's Disease  (multiple sites) SNIFF: Study of Nasal Insulin to Fight Forgetfulness  (multiple sites)   Brain Imaging Tau PET Imaging in the Dominantly Inherited Alzheimer Network (St. Louis, MO)   Other Dementias HEADWAY-DLB: RVT-101 for Dementia with Lewy Bodies (multiple sites) LEFFTDS: Longitudinal Evaluation of Familial Frontotemporal Dementia (multiple sites) Natural History of Amyloid Deposition in Adults with Down Syndrome (Pittsburgh, PA, and Madison, WI)   Registries Alzheimer's Prevention Registry (nationwide)—get information and updates about participating in future Alzheimer's prevention trials. Brain Health Registry (nationwide)—sign up for an online study of brain health and learn about possible research-study opportunities. GeneMatch (nationwide)—enroll to get matched to Alzheimer's genetics studies     Get more information about these and other Alzheimer's clinical trials. Or, call the ADEAR Center at 1-800-438-4380 (toll-free) or email adear@nia.nih.gov. Help us spread the word about Alzheimer's and related clinical trials! Forward this email to anyone who may be interested. Share via social media: Looking for #Alzheimer's and related #clinicaltrials? Find the latest information here:  http://1.usa.gov/Y1zmEN   STAY CONNECTED          SUBSCRIBER SERVICES Manage Subscriptions | Subscription Help | Contact Us This email was sent to rssproject471@gmail.com using GovDelivery, on behalf of: National Institute on Aging · 31 Center Drive, MSC 2292 · Bethesda, MD · 20892 · 800-222-2225

Tweet

Postingan terkait:

— Thursday, August 4, 2016 — Add Comment